This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Gain insight into research trends and influential papers with Research Intelligence.
doi.org/10.1016/s1473-3099(18)30731-x
Other

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

..., Joseph Sliman
8
The Lancet Infectious Diseases36.40
Volume: 19, Issue: 5, Pages: 487 - 496
Published: Mar 16, 2019
Abstract
No abstract.
Paper Fields
Paper Details
Title
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial
DOI
doi.org/10.1016/s1473-3099(18)30731-x
Published Date
Mar 16, 2019
Journal
The Lancet Infectious Diseases
Volume
19
Issue
5
Pages
487 - 496
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.